Drugs / Vebreltinib
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07050316 | Mar → Sep 2025 | nervous system disorder | Ceres Brain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05367388 | May → Nov 2022 | — | Apollomics Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT04557306 | Sep 2020 → Oct 2021 | cancer | CHABiotech CO., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02978261 | Sep 2016 → Apr 2018 | glioma | Beijing Pearl Biotechnology Limited Liability Company | Completed | No outcome recorded |
| Phase 1 | NCT02896231 | Apr 2016 → Oct 2019 | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07655622 | Jul 2026 → Dec 2027 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07087223 | Apr 2025 → Apr 2027 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06343064 | Jun 2023 → Dec 2026 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04743505 | Jan 2022 → Jan 2027 expected | non-small cell lung carcinoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03655613 | Sep 2018 → Dec 2021 | hepatocellular carcinoma, renal cell carcinoma | Apollomics (Australia) Pty. Ltd. | Terminated | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07549061 | Mar 2026 → May 2028 expected | lung neoplasm | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07153887 | Sep 2025 → Jul 2026 overdue | clear cell sarcoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07156604 | Sep 2025 → Sep 2027 expected | non-small cell lung carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07153770 | Sep 2025 → Sep 2027 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06780592 | Jan → Dec 2025 overdue | glioblastoma | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06644313 | Nov 2024 → Nov 2029 expected | lung cancer | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06739395 | Nov 2024 → Dec 2026 expected | cancer | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06827145 | Oct 2024 → Sep 2026 expected | non-small cell lung carcinoma | National Cancer Center, China | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06574347 | Aug 2024 → Oct 2026 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04258033 | Jan 2020 → May 2024 | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Completed | No outcome recorded |
| Phase 2 | NCT03175224 | Sep 2017 → Mar 2026 overdue | brain neoplasm, colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +5 | Apollomics Inc. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06105619 | Oct 2018 → Apr 2023 overdue | glioblastoma | Beijing Pearl Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06930794 | Jul 2025 → Feb 2029 expected | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06970782 | May 2025 → Dec 2027 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05989542 | Oct 2023 → Sep 2026 expected | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vebreltinib | “APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase...” NCT05367388 ↗14“vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition (MET)” PMID 39058972 ↗ Jul 2024 |
| Known as | APL-101 | “vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition (MET)” PMID 39058972 ↗ Jul 2024 |
| Known as | Bozitinib | “vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition (MET)” PMID 39058972 ↗ Jul 2024 |
| Known as | CBI-3103 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650443 ↗ |
| Known as | CBT-101 | “vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition (MET)” PMID 39058972 ↗ Jul 2024 |
| Known as | PLB-1001 | “Furthermore, we describe a MET kinase inhibitor, PLB-1001, that demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells in preclinical models.” PMID 30343896 ↗ Oct 20186“vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition (MET)” PMID 39058972 ↗ Jul 2024 |
| Action | Inhibit | “PLB1001 is a potent selective c-Met inhibitor.” NCT02896231 ↗ |
| Modality | Cell therapy | “CBT101, an Autologous Natural Killer Cell” NCT04557306 ↗ |
| Route | Oral | “PLB1001 administered orally to patients” NCT02978261 ↗ |
| Target | MET | “PLB1001 acts on cancer by blocking abnormal cMET-mediated signaling” NCT02978261 ↗ |